GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years and as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).

Help your patients living with MMN

MMN symptoms can get in the way of daily tasks like tying a shoelace, buttoning a coat, or even gripping a utensil to eat.1

GAMMAGARD LIQUID is the first and only FDA-approved treatment for adults with MMN.2 With clinically-demonstrated efficacy in improved muscle strength and reduced disability,* GAMMAGARD LIQUID can help your patients take on simple acts of self-care—and redefine their lives with MMN.2

*In a 60-week clinical study with 44 adults with MMN, GAMMAGARD LIQUID was shown to improve or maintain grip strength and reduce disability compared to placebo.

Stethoscope icon.

Diagnosis considerations

MMN is a rare immune-mediated, progressive motor neuropathy. A diagnosis of MMN can be elusive, often presenting with symptoms similar to those of other neuropathies.3,4 However, early detection is important, as many MMN patients respond to treatment.4 Get an overview of MMN and when to consider it in your diagnostic workup.

Review MMN info
Graph showing an increase.

Demonstrated efficacy

When considering treatment for adults with MMN, you may be interested in offering the only FDA-approved option. The safety and efficacy of GAMMAGARD LIQUID were established in the largest controlled clinical trial for MMN to date.2 Review study design details and see the results.

See efficacy data
Safety icon.

Established safety profile

Of course, safety is always an important consideration when initiating and monitoring patients throughout the infusion experience. The safety profile for GAMMAGARD LIQUID was established in the largest controlled clinical trial for MMN to date.2,5 Review the details now.

MMN safety profile